Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update
(NasdaqGM:RYTM), — Third quarter 2025 net product revenue from global sales of IMCIVREE(R) (setmelanotide) of $51.3 million — — December 20, 2025 PDUFA goal date set for sNDA for setmelanotide in acquired hypothalamic obesity — — Company is on track to report preliminary results from setmelanotide Phase 2 trial in Prader-Willi syndrome in fourth quarter […]